

Robert Huddart

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8906319/robert-huddart-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45
papers

1,174
citations

16
h-index

34
g-index

60
ext. papers

1,474
ext. citations

4.4
avg, IF

3.65
L-index

#	Paper	IF	Citations
45	Recognising the challenges of implementing multi-centre adaptive plan of the day radiotherapy.. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2022 , 21, 31-35	1.9	0
44	Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101199	2.3	1
43	Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 1129-1138	4	0
42	Radiographer-led online image guided adaptive radiotherapy: A qualitative investigation of the therapeutic radiographer role. <i>Radiography</i> , 2021 , 27, 1085-1093	2	5
41	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1553-1562	2.2	13
40	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1563-1574	2.2	19
39	PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. <i>Future Oncology</i> , 2021 , 17, 137-149	3.6	5
38	Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 110, 412-424	4	7
37	Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). <i>Clinical Cancer Research</i> , 2021 , 27, 1882-1892	12.9	6
36	Reply to Santhanam Sundar and Paul Symonds Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. <i>Eur Urol</i> 2021 ;79:307-15. <i>European Urology</i> , 2021 , 80, e51-e52	10.2	
35	Recent advances in testicular germ cell tumours. <i>Faculty Reviews</i> , 2021 , 10, 67	1.2	0
34	Outcomes of Postchemotherapy Retroperitoneal Lymph Node Dissection from a High-volume UK Centre Compared with a National Data Set. <i>European Urology Open Science</i> , 2021 , 33, 83-88	0.9	1
33	Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic - Rapid Review. <i>Clinical Oncology</i> , 2020 , 32, 347-353	2.8	6
32	Genomic landscape of platinum resistant and sensitive testicular cancers. <i>Nature Communications</i> , 2020 , 11, 2189	17.4	23
31	Protocol for hypofractionated adaptive radiotherapy to the bladder within a multicentre phase II randomised trial: radiotherapy planning and delivery guidance. <i>BMJ Open</i> , 2020 , 10, e037134	3	18
30	Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance. <i>BMJ Open</i> , 2020 , 10, e041005	3	6
29	Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa022	4.6	5

28	Quality assuring "Plan of the day" selection in a multicentre adaptive bladder trial: Implementation of a pre-accrual IGRT guidance and assessment module. <i>Clinical and Translational Radiation Oncology</i> , 2019 , 19, 27-32	4.6	11
27	Patterns of recurrence after prostate bed radiotherapy. <i>Radiotherapy and Oncology</i> , 2019 , 141, 174-180	5.3	10
26	MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 104, 809-818	4	17
25	Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. <i>Clinical Cancer Research</i> , 2019 , 25, 4104-4116	12.9	15
24	EP-1566 MR-guided online adaptive radiotherapy: First experience in the UK. <i>Radiotherapy and Oncology</i> , 2019 , 133, S845	5.3	2
23	Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 459-468	7.3	6
22	Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene. <i>European Urology</i> , 2018 , 73, 828-831	10.2	38
21	SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial. <i>Trials</i> , 2018 , 19, 216	2.8	6
20	Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 458-465.e2	3.3	2
19	Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP. <i>Advances in Urology</i> , 2018 , 2018, 8781698	1.6	12
18	Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuited for Radical Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 115-122	4	35
17	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2636-43	2.2	60
16	PLUTO: A randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 430-430	2.2	5
15	Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 94, 1022-30	4	35
14	Magnitude of observer error using cone beam CT for prostate interfraction motion estimation: effect of reducing scan length or increasing exposure. <i>British Journal of Radiology</i> , 2015 , 88, 20150208	3.4	6
13	Defining bowel dose volume constraints for bladder radiotherapy treatment planning. <i>Clinical Oncology</i> , 2015 , 27, 22-9	2.8	14
12	Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. <i>Nature Communications</i> , 2015 , 6, 5973	17.4	128
11	Phase I dose-escalated image-guided adaptive bladder radiotherapy study: Results of first dose cohort (68Gy).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 291-291	2.2	1

10	Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. <i>Lancet Oncology, The</i> , 2012 , 13, 43-54	21.7	253
9	Adaptive-predictive organ localization using cone-beam computed tomography for improved accuracy in external beam radiotherapy for bladder cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 79, 705-12	4	62
8	The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 Familial malignant testicular germ cell tumor kindred. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010 , 28, 492-9	2.8	35
7	Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature. <i>Genes Chromosomes and Cancer</i> , 2008 , 47, 34-42	5	71
6	Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. <i>Human Molecular Genetics</i> , 2006 , 15, 443-51	5.6	127
5	Prostate Radiotherapy: Evaluating the Effect of Bladder and Rectal Changes on Prostate Movement-A CT Study. <i>Trends in Medical Research</i> , 2006 , 1, 55-65	0.2	6
4	Activating mutations and/or expression levels of tyrosine kinase receptors GRB7, RAS, and BRAF in testicular germ cell tumors. <i>Neoplasia</i> , 2005 , 7, 1047-52	6.4	55
3	Familial ovarian germ cell cancer: report and review. <i>American Journal of Medical Genetics Part A</i> , 1999 , 84, 43-6		25
2	Management of germ cell tumours of the testis. <i>Lancet, The</i> , 1999 , 353, 410	40	
1	Phase one clinical trial of the use of focused ultrasound surgery for the treatment of soft-tissue tumors 1998 ,		13